LCM
AGMB

Laurion Capital Management’s AgomAb Therapeutics NV AGMB Stock Holding History

Laurion Capital Management’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$525K – 576
2026
Q1 		$525K Buy
+50,000
New +$708K 0.02% 289

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Laurion Capital Management's AGMB Position: Q2 2026 in Review

Laurion Capital Management sold out of AgomAb Therapeutics NV (AGMB) in Q2 2026, closing a stake of 50,000 shares — an estimated $525K sold.

Laurion Capital Management first reported a position in AGMB in Q1 2026 and held it in 1 quarter. The position peaked at $525K in Q1 2026. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • Laurion Capital Management reported no remaining AgomAb Therapeutics NV position as of Q2 2026 after selling out during the quarter.
  • Laurion Capital Management sold 50,000 AgomAb Therapeutics NV shares in Q2 2026, an estimated $525K.
  • Laurion Capital Management first reported a position in AgomAb Therapeutics NV in Q1 2026 and held it in 1 quarter.
  • Laurion Capital Management's AgomAb Therapeutics NV position peaked at $525K in Q1 2026.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.